Login to Your Account

Amgen axes brodalumab development; Astrazeneca keeps mum on next steps

By Marie Powers
News Editor

Tuesday, May 26, 2015
After Friday's market close, while much of the U.S. had already turned its attention to the long Memorial Day weekend, Amgen Inc. quietly axed its stake in brodalumab, the much-heralded IL-17 inhibitor that was part of a co-development and commercialization deal with partner Astrazeneca plc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription